Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients
暂无分享,去创建一个
F. Villarroya | F. Vidal | M. Giralt | M. C. Cabeza | P. Domingo | J. M. Gallego-Escuredo | M. Mateo | M. Gutiérrez | J. Domingo | Àngels Fontanet
[1] F. Villarroya,et al. Adipose tissue biology and HIV-infection. , 2011, Best practice & research. Clinical endocrinology & metabolism.
[2] S. Kliewer,et al. FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.
[3] F. Villarroya,et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients , 2010, AIDS.
[4] S. Kliewer,et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. , 2010, Molecular endocrinology.
[5] Kathryn A. Lee,et al. Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults. , 2010, Metabolic syndrome and related disorders.
[6] N. Itoh. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease , 2010, Cell and Tissue Research.
[7] J. Flier,et al. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.
[8] M. Martínez-Chantar,et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.
[9] K. Brouwer,et al. Plasma Bile Acid Concentrations in Patients with Human Immunodeficiency Virus Infection Receiving Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity , 2010, Pharmacotherapy.
[10] Yang Li,et al. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis , 2009, Aging.
[11] B. Lemon,et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice , 2009, Proceedings of the National Academy of Sciences.
[12] R. Haubrich,et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment , 2009, AIDS.
[13] Sushant Bhatnagar,et al. Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis* , 2009, Journal of Biological Chemistry.
[14] F. Villarroya,et al. HIV-1 Infection and the PPARγ-Dependent Control of Adipose Tissue Physiology , 2008, PPAR research.
[15] Feng Liu,et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.
[16] Stacey A. Jones. Mini-review: endocrine actions of fibroblast growth factor 19. , 2008, Molecular pharmaceutics.
[17] G. Boden,et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[18] S. Kliewer,et al. Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.
[19] F. Mehrbod,et al. Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling , 2007, Journal of cellular physiology.
[20] T. Lundåsen,et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man , 2006, Journal of internal medicine.
[21] F. Villarroya,et al. HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy , 2005, Antiviral therapy.
[22] K. Lichtenstein. Redefining Lipodystrophy Syndrome: Risks and Impact on Clinical Decision Making , 2005, Journal of acquired immune deficiency syndromes.
[23] J. Gromada,et al. FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.
[24] I. James,et al. Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level , 2002, Antiviral therapy.
[25] L. Lönn,et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. , 2002, Obesity research.
[26] C. Bouchard,et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. , 1996, The American journal of clinical nutrition.
[27] K. Uekama,et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. , 1995, Clinical chemistry.
[28] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[29] M. Haluzík,et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. , 2011, Physiological research.
[30] D. French,et al. Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .